8-K: GRAIL Reports Q1 2025 Financial Results: Galleri Revenue Up 22% in the U.S., NHS-Galleri Trial Shows Positive Top-Line Results

GRAIL, Inc. announced its Q1 2025 financial results, highlighting a 22% year-over-year increase in U.S. Galleri revenue and positive top-line results from the NHS-Galleri trial.

Summary

• GRAIL, Inc. reported its financial results for the first quarter of 2025.
• Total revenue reached $31.8 million, a 19% increase compared to the same period last year.
• Galleri revenue was $29.1 million, representing a 24% year-over-year growth.
• U.S. Galleri revenue specifically grew by 22% year-over-year, reaching $28.7 million.
• The net loss for the quarter was $106.2 million, which includes $34.6 million in amortization of Illumina acquisition-related intangible items.
• The gross loss was $19.9 million.
• Adjusted gross profit was $14.3 million, and adjusted EBITDA was $(98.7) million.
• GRAIL completed over 37,000 Galleri tests in the first quarter of 2025.
• The company's cash position as of March 31, 2025, was $677.9 million, providing runway into 2028.
• Positive top-line results were announced from the prevalent screening round of the NHS-Galleri trial, showing a substantially higher positive predictive value (PPV) than observed in the PATHFINDER study.
• Final results from the NHS-Galleri trial are expected in mid-2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to revenue growth, improved financial metrics, and promising trial results, but tempered by ongoing losses and regulatory uncertainties.

Positives

• Total revenue increased by 19% year-over-year.
• U.S. Galleri revenue grew by 22% year-over-year.
• Net loss improved by 51% compared to the same quarter last year.
• Adjusted EBITDA improved by 35% compared to the same quarter last year.
• The company has a strong cash position of $677.9 million, providing runway into 2028.
• Positive top-line results from the NHS-Galleri trial indicate promising performance of the Galleri test.
• Partnership with athenahealth to integrate Galleri test ordering into their EHR platform.

Negatives

• The company reported a net loss of $106.2 million for the quarter.
• The company reported a gross loss of $19.9 million for the quarter.
• Adjusted EBITDA was still negative at $(98.7) million.

Risks

• The company is still operating at a loss, although the loss has decreased compared to the previous year.
• The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration.
• Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
• The final results from the NHS-Galleri trial may be inconsistent with interim results.

Future Outlook

GRAIL plans to share registrational data from the PATHFINDER 2 study later this year and final results from the NHS-Galleri trial in mid-2026, and submit data from the prevalent screening round of the NHS-Galleri trial as part of their premarket approval application in the first half of 2026.

Management Comments

• Bob Ragusa, Chief Executive Officer at GRAIL, stated that they are pleased with the continued U.S. commercial growth of Galleri and recent steps to streamline the test ordering process and increase test access.
• Ragusa added that they remain focused on developing the market for population scale multi-cancer early detection, advancing Galleri to unlock broad access, and cost efficiency.
• Ragusa also stated that they are very pleased with the initial results from the NHS-Galleri trial.

Industry Context

GRAIL's focus on multi-cancer early detection (MCED) aligns with a growing trend in the healthcare industry towards proactive screening and early intervention. The partnerships with athenahealth and Kate Walsh indicate a strategic effort to increase market penetration and public awareness of MCED testing.

Comparison to Industry Standards

• The PATHFINDER study demonstrated a PPV of 43%, CSO accuracy of 88%, and specificity of 99.5% for Galleri.
• Exact comparison to industry standards is difficult without knowing the specific benchmarks for MCED tests, as the field is relatively new.
• However, the reported PPV in the NHS-Galleri trial being 'substantially higher' than the PATHFINDER study suggests a positive trend in test performance.
• Companies like Exact Sciences (maker of Cologuard) and Guardant Health (focusing on liquid biopsies for cancer treatment selection and monitoring) are also key players in the broader cancer diagnostics market, but their specific technologies and target markets differ from GRAIL's.

Stakeholder Impact

• Shareholders: The improved financial performance and positive trial results could positively impact shareholder value.
• Employees: Continued growth and a strong cash position provide job security and potential for future opportunities.
• Customers: The Galleri test offers a proactive screening tool for early cancer detection.
• Healthcare Providers: Partnerships with platforms like athenahealth streamline the test ordering process and increase access for patients.

Next Steps

• GRAIL plans to share registrational data from the PATHFINDER 2 study later this year.
• GRAIL plans to share final results from the NHS-Galleri trial in mid-2026.
• GRAIL plans to submit data from the prevalent screening round of the NHS-Galleri trial as part of their premarket approval application in the first half of 2026.

Key Dates

Keywords

Galleri, multi-cancer early detection, MCED, NHS-Galleri trial, financial results, revenue, GRAIL